Hyperplasia — Increased Cell Growth in Tissues

Hyperplasia is a physiological or pathological response characterised by an accelerated rate of cell division, leading to an abnormally high concentration of cells in a specific tissue. Under a microscope, these cells retain a normal, organised architecture and do not invade surrounding structures, distinguishing them from malignant cells. It frequently arises in response to persistent hormonal stimulation, chronic physical irritation, or ongoing tissue repair processes.

Pathologists broadly classify hyperplasia as typical or atypical. In typical hyperplasia, cellular appearance remains largely unremarkable. Atypical hyperplasia involves minor architectural or structural abnormalities. While atypical variants remain strictly non-cancerous, they are clinically significant because they can indicate an increased vulnerability to future malignant transformation.

Receiving a pathology report noting hyperplasia can cause anxiety, but understanding its specific type brings clarity to your care plan. Knowing whether hyperplasia is typical or atypical helps your oncology team gauge your individual risk profile. It guides decisions on whether you simply need standard cancer screening, increased surveillance intervals, or preventive strategies. Understanding this finding ensures you neither undergo unnecessary aggressive procedures nor overlook a potential early warning sign.

Hyperplasia cannot be confirmed by physical examination or imaging alone; it requires tissue sampling through a biopsy or surgical excision. A pathologist examines the cellular architecture under a microscope to confirm the diagnosis and check for atypia. Imaging studies, such as mammography, breast MRI, or transvaginal ultrasound, often detect the initial tissue thickening that prompts the biopsy.

Hyperplasia is most frequently discussed in the context of breast and uterine health. In breast tissue, conditions like usual ductal hyperplasia or atypical ductal hyperplasia are monitored for links to breast carcinoma. In gynaecology, endometrial hyperplasia, often driven by excess oestrogen, can precede endometrial cancer. Benign prostatic hyperplasia (BPH) is extremely common in the prostate gland, though it does not directly increase prostate cancer risk.

Typical hyperplasia often requires no active intervention beyond routine screening. When atypical hyperplasia is identified, clinical management may involve surgical excision to rule out adjacent malignancy. Depending on the tissue, preventive endocrine therapy (such as selective oestrogen receptor modulators for breast tissue or progestins for endometrial hyperplasia) may be recommended to reduce future cancer risk.